Evidence map›Paper›PMID 36196767›Full record

ArticleKorean journal of radiology2022

Sonazoid™ versus SonoVue

Hyo-Jin Kang, Jeong Min Lee, Jeong Hee Yoon, Jeongin Yoo, Yunhee Choi, Ijin Joo, Joon Koo Han

Registry-linked trialOpen access · greenAbstract readEquivalence Trial
In one paragraph

Article in Korean journal of radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04847726 (Perfluorobutane-enhanced Ultrasound as a Diagnostic Tool for Hepatocellular Carcinoma in Individuals With High Risk), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04847726 nacompletednot on this map

Perfluorobutane-enhanced Ultrasound as a Diagnostic Tool for Hepatocellular Carcinoma in Individuals With High Risk: Intraindividual Comparison With Sulfur Hexafluoride-enhanced Ultrasound

TypeinterventionalSponsorSeoul National University HospitalRan2020 to 2021Enrolled110ConditionsHepatocellular CarcinomaArmscontrast enhanced ultrasound, Dynamic CT, Liver MRI
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Compared with SonoVueQuantitative imaging in medicine and surgery · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Recent Advances in Ablative Therapies for HCC.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hyo-Jin KangDepartment of Radiology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-6771-2112
Jeong Min LeeDepartment of Radiology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0003-0561-8777
Jeong Hee YoonDepartment of Radiology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-9925-9973
Jeongin YooDepartment of Radiology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-3267-2544
Yunhee ChoiDivision of Medical Statistics, Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0001-5305-1803
Ijin JooDepartment of Radiology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-1341-4072
Joon Koo HanDepartment of Radiology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0001-5916-5545
Seoul National University · KRSeoul National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine whether Sonazoid-enhanced ultrasound (SZUS) was noninferior to SonoVue-enhanced ultrasound (SVUS) in diagnosing hepatocellular carcinoma (HCC) using the same diagnostic criteria. MATERIALS AND

methodsThis prospective, single-center, noninferiority study (NCT04847726) enrolled 105 at-risk participants (71 male; mean age ± standard deviation, 63 ± 11 years; range, 26-86 years) with treatment-naïve solid hepatic nodules (≥ 1 cm). All participants underwent same-day SZUS (experimental method) and SVUS (control method) for one representative nodule per participant. Images were interpreted by three readers (the operator and two independent readers). All malignancies were diagnosed histopathologically, while the benignity of other lesions was confirmed by follow-up stability or pathology. The primary endpoint was per-lesion diagnostic accuracy for HCC pooled across three readers using the conventional contrast-enhanced ultrasound diagnostic criteria, including arterial phase hyperenhancement followed by mild (assessed within 2 minutes after contrast injection) and late (≥ 60 seconds with a delay of 5 minutes) washout. The noninferiority delta was -10%p. Furthermore, different time delays were compared as washout criteria in SZUS, including delays of 2, 5, and > 10 minutes.

resultsA total of 105 lesions (HCCs [n = 61], non-HCC malignancies [n = 19], and benign [n = 25]) were evaluated. Using the 5-minutes washout criterion, per-lesion accuracy of SZUS pooled across the three readers (72.4%; 95% confidence interval [CI], 64.1%-79.3%) was noninferior to that of SVUS (71.4%; 95% CI, 63.1%-78.6%), meeting the statistical criterion for non-inferiority (difference of 0.95%p; 95% CI, -3.8%p-5.7%p). The arterial phase hyperenhancement combined with the 5-minutes washout criterion showed the same sensitivity as that of the > 10-minutes criterion (59.0% vs. 59.0%,

conclusionSZUS was noninferior to SVUS for diagnosing HCC in at-risk patients using the same diagnostic criteria. No significant improvement in HCC diagnosis was observed by extending the washout time delay from 5 to 10 minutes.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAdultAgedAged, 80 and overContrast MediaFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPhospholipidsProspective StudiesSensitivity and SpecificitySulfur HexafluorideUltrasonographycontrast agent BR1Contrast MediaPhospholipidsSulfur HexafluorideHepatocellular carcinomaNoninferiority testSonazoid-enhanced ultrasoundSonoVue-enhanced ultrasound

Identifiers

PMID36196767
PMCPMC9614293
OpenAlexW4302275968

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.